3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
32
Thoracic
1
Gastrointestinal
1
Dermatologic
1
Conditions
Melanoma
777
Carcinoma, Non-Small-Cell Lung
198
Lymphoma, T-Cell, Cutaneous
171
Carcinoma, Renal Cell
139
Neoplasms
130
Mycosis Fungoides
120
Breast Neoplasms
114
Lymphoma, Large B-Cell, Diffuse
112
Colorectal Neoplasms
111
Lymphoma, Non-Hodgkin
110
Sezary Syndrome
109
Lymphoma, Follicular
107
Neoplasm Metastasis
105
Lymphoma
103
Leukemia, Lymphocytic, Chronic, B-Cell
103
Lymphoma, Mantle-Cell
100
Lymphoma, B-Cell, Marginal Zone
98
Hodgkin Disease
98
Precursor Cell Lymphoblastic Leukemia-Lymphoma
97
Burkitt Lymphoma
94
Squamous Cell Carcinoma of Head and Neck
92
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
92
Lymphoma, Large-Cell, Immunoblastic
86
Lymphoma, Large-Cell, Anaplastic
86
Ovarian Neoplasms
84
Lung Neoplasms
80
Immunoblastic Lymphadenopathy
79
Sarcoma
67
Pancreatic Neoplasms
65
Head and Neck Neoplasms
64
Interventions
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Non-Muscle Invasive Bladder Neoplasms
×
Dermatologic
×
Clear all
NCT06448364
2024-11-06
LTbR
Pfizer
Phase 1
Terminated
4 enrolled